1
|
Catapano F, Ellis M, Torelli S, Chambers D, Evangelista T, Leturcq F, Natera-de Benito D, Jimenez-Mallebrera C, Marini-Bettolo C, Charlton R, Stenzel W, Dittmayer C, Schänzer A, Hilton D, Lilleker J, Roncaroli F, Sarkozy A, Muntoni F, Phadke R. DMD - BIOMARKERS. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
2
|
Ortez C, Carrera L, Exposito J, Natera D, Zambudio S, Colomer J, Bazán A, Pareja A, Bobadilla E, Sáez V, Medina J, Jou C, Codina A, Corbera J, Yubero D, Martorell L, Jimenez-Mallebrera C, Nascimento A. AUTOPHAGIC MYOPATHIES / MYOFIBRILLAR MYOPATHIES / DISTAL MYOPATHIES / POMPE DISEASE. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
3
|
Bolduc V, Foley A, Solomon Degefa H, Sarathy A, Donkervoort S, Hu Y, Zhou H, Cummings B, Lek M, Regev O, Jimenez-Mallebrera C, Allamand V, Ferlini A, Wilton S, Hanssen E, Lamandé S, MacArthur D, Wagener R, Muntoni F, Bönnemann C. O.10A novel target for splice-modulating therapies: a common pseudoexon-inducing mutation that causes a severe collagen VI-related muscular dystrophy. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
4
|
Roldán M, Bazaga A, Badosa C, Porta J, Jimenez-Mallebrera C. P.385Automated diagnosis of collagen VI related muscular dystrophies using advanced image analysis and machine learning. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
5
|
Trifunov S, Badosa C, Natera de Benito D, Exposito Escudero J, Ortez C, Medina J, Carrera L, Nascimento A, Jimenez-Mallebrera C. P.152A longitudinal study of miRNA biomarkers in paediatric Duchenne muscular dystrophy patients. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Natera de Benito D, Jou C, Jimenez-Mallebrera C, Ortez C, Codina A, Carrera Garcia L, Exposito Escudero J, Colomer Oferil J, Palau F, Nascimento A. P.242Phenotypic variability in a cohort of patients with TTN-related congenital myopathy. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
7
|
Ortez C, Medina J, Vigo M, Moya O, Padros N, Natera De Benito D, Carrera L, Colomer J, Zschaeck I, Jimenez-Mallebrera C, Solé L, Cubells M, Jou C, Nascimento A. DMD CLINICAL THERAPIES I. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
8
|
Reghan Foley A, Donkervoort S, Bolduc V, Hu Y, Cummings B, Lek M, Sarkozy A, Jimenez-Mallebrera C, Butterfield R, Lamande S, Kirschner J, Allamand V, Stojkovic T, Quijano-Roy S, Gualandi F, Ferlini A, Bertini E, MacArthur D, Muntoni F, Bönnemann C. A common COL6A1 deep-intronic pseudo-exon inserting mutation causes a distinct phenotype of Ullrich congenital muscular dystrophy. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Natera-de Benito D, Alarcon M, Ortez C, Nascimento A, Jou C, Medina J, Vigo M, Codina A, Frongia A, Colomer J, Jimenez-Mallebrera C. Clinical and genetic characterization of collagen VI-related myopathies: difficulties in phenotypic characterization in the first years of life. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.052] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Ortez C, Natera D, Colomer J, Itzep D, Alarcón M, Frongia A, Jou C, Codina A, Jimenez-Mallebrera C, Martorell L, Biancalana V, González L, Gallano P, Nascimento A. X-Linked myotubular myopathy (XLMTM): phenotypic variability. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Nascimento A, Ortez C, Colomer J, Natera D, Frongia A, Alarcon M, Itzep D, Jou C, Codina A, Corbera J, Rodriguez M, Rodriguez M, González L, Gallano P, Sacher M, Topf A, Straub V, Jimenez-Mallebrera C. A case of severe encephalopathy and movement disorder due to mutations in the TRAPPC11 gene. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
12
|
Nascimento A, Ortez C, Jou C, Corbera J, Codina A, Frongia A, Borras A, Jimenez-Mallebrera C, Colomer J. Lambert–Eaton syndrome in children, a rare unrecognized treatable neuromuscular disorder: Is there any useful feature in the muscle biopsy? Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Ortez C, Jou C, Campistol J, Nascimento A, Jimenez-Mallebrera C, Topf A, Johnson K, Straub V, Codina A, Corbera J, Colomer J. Exercise intolerance and myalgia: First clinical sign of a primary alpha-sarcoglycanopathy. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
14
|
Llano-Diez M, Ortez C, Alvarez L, Paco S, Kalko S, Jou C, Colomer J, Nascimento A, Jimenez-Mallebrera C. Digital PCR quantification of miR-30c and miR-181a as serum biomarkers in Duchenne muscular dystrophy. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.265] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
15
|
Natera-de Benito D, Nascimento A, Abicht A, Ortez C, Jou C, Müller JS, Evangelista T, Töpf A, Thompson R, Jimenez-Mallebrera C, Colomer J, Lochmüller H. KLHL40-related nemaline myopathy with a sustained, positive response to treatment with acetylcholinesterase inhibitors. J Neurol 2016; 263:517-23. [DOI: 10.1007/s00415-015-8015-x] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2015] [Revised: 12/26/2015] [Accepted: 12/28/2015] [Indexed: 11/28/2022]
|
16
|
Nascimento A, Ortez C, Sariego A, Gerotina E, Armstrong J, Sierra C, Artuch R, Jou C, Jimenez-Mallebrera C, Colomer J. Hereditary spastic paraplegia and peroxisome biogenesis disorders: Case report of a patient with mutations in PEX10 gene. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
17
|
Jou C, Ortez C, Jimenez-Mallebrera C, Romero N, Bouchier G, Fernández-Marmiesse A, Couce M, Carrascosa-Romero M, Blancas A, Ribalta T, Colomer J, Nascimento A. A novel form of CAP myopathy in absence of heart disease associated with recessive TTN gene mutations. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
18
|
Juan-Mateu J, González-Quereda L, Rodriguez M, Jou C, Nascimento A, Jimenez-Mallebrera C, Colomer J, Baiget M, Olive M, Gallano P. P.2.14 Isolated cognitive abnormalities associated to DMD mutations. Neuromuscul Disord 2013. [DOI: 10.1016/j.nmd.2013.06.419] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
Ortez C, Nascimento A, Jou C, Jimenez-Mallebrera C, Paco S, Corbera J, Viancalana V, Colomer J. P.4.8 X-linked benign form of myotubular myopathy (XLMTM) with necklace fibres: A case report. Neuromuscul Disord 2013. [DOI: 10.1016/j.nmd.2013.06.446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
20
|
Jou C, Nascimento A, Ortez C, Olivè M, Ferrer I, Cusí V, Rovira C, Sunol M, Corbera J, Colomer J, Jimenez-Mallebrera C. P.17.6 Globular inclusions are a frequent finding in infantile Pompe’s disease. Neuromuscul Disord 2013. [DOI: 10.1016/j.nmd.2013.06.656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
21
|
Casserras T, Kalko S, Paco S, Jou C, Nascimento A, Ortez C, Colomer J, Jimenez-Mallebrera C. P.1.4 Gene expression profile of collagen VI deficient human fibroblasts. Neuromuscul Disord 2013. [DOI: 10.1016/j.nmd.2013.06.388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
22
|
Nascimento A, Grazia S, Otez C, Poo P, Polo A, Jimenez-Mallebrera C, Baas F, Galvez H, Iturriaga C, Colomer J. G.P.87 Demyelinating neuropathy caused by point mutations in PMP22 gene: Phenotype variability. Neuromuscul Disord 2012. [DOI: 10.1016/j.nmd.2012.06.217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
23
|
Kim J, Jimenez-Mallebrera C, Foley AR, Fernandez-Fuente M, Brown SC, Torelli S, Feng L, Sewry CA, Muntoni F. Flow cytometry analysis: a quantitative method for collagen VI deficiency screening. Neuromuscul Disord 2011; 22:139-48. [PMID: 22075033 PMCID: PMC3657173 DOI: 10.1016/j.nmd.2011.08.006] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2011] [Revised: 08/02/2011] [Accepted: 08/11/2011] [Indexed: 12/12/2022]
Abstract
Mutations in COL6A1, COL6A2 and COL6A3 genes result in collagen VI myopathies: Ullrich congenital muscular dystrophy (UCMD), Bethlem myopathy (BM) and intermediate phenotypes. At present, none of the existing diagnostic techniques for evaluating collagen VI expression is quantitative, and the detection of subtle changes in collagen VI expression remains challenging. We investigated flow cytometry analysis as a means of quantitatively measuring collagen VI in primary fibroblasts and compared this method with the standard method of fibroblast collagen VI immunohistochemical analysis. Eight UCMD and five BM molecularly confirmed patients were studied and compared to five controls. Flow cytometry analysis consistently detected a reduction of collagen VI of at least 60% in all UCMD cases. In BM cases the levels of collagen VI were variable but on average 20% less than controls. Flow cytometry analysis provides an alternative method for screening for collagen VI deficiency at the protein level in a quantitative, time and cost-effective manner.
Collapse
Affiliation(s)
- J Kim
- Dubowitz Neuromuscular Centre, University College London Institute of Child Health, London, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Juan-Mateu J, Verdura E, Rodriguez M, Gonzalez-Quereda L, Colomer J, Díaz-Manera J, Gallardo E, Gonzalez-Mera L, Macaya A, Munell F, Nascimento A, Navarro C, Olive M, Pascual J, Pou A, Rivas E, Roig M, Baiget M, Gallano P, Madruga M, Jimenez-Mallebrera C. P1.18 Dystrophinopathy in manifesting female carriers: Clinical and genetic characterization in a cohort of 20 patients. Neuromuscul Disord 2011. [DOI: 10.1016/j.nmd.2011.06.778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
25
|
Jimenez-Mallebrera C, Jou C, Corbera J, Nascimento A, Gualandi F, Sabatelli P, Colomer J. P1.13 Pathological spectrum of collagen VI related myopathies: Does the pathology tell us something about the disease? Neuromuscul Disord 2010. [DOI: 10.1016/j.nmd.2010.07.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
26
|
Colomer J, Nascimento A, Ortez C, Jou C, Corbera J, González F, Nunes T, Sabatelli P, Gualandi F, Jimenez-Mallebrera C. P1.09 Clinical features in collagen VI deficiency. Neuromuscul Disord 2010. [DOI: 10.1016/j.nmd.2010.07.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
27
|
Hicks D, Lampe AK, Laval SH, Allamand V, Jimenez-Mallebrera C, Walter MC, Muntoni F, Quijano-Roy S, Richard P, Straub V, Lochmüller H, Bushby KMD. Cyclosporine A treatment for Ullrich congenital muscular dystrophy: a cellular study of mitochondrial dysfunction and its rescue. Brain 2009; 132:147-55. [DOI: 10.1093/brain/awn289] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Hicks D, Lampe A, Laval S, Allamand V, Jimenez-Mallebrera C, Walter M, Muntoni F, Quijano-Roy S, Richard P, Straub V, Lochmuller H, Bushby K. Response to letter from Bernardi. Brain 2009. [DOI: 10.1093/brain/awp022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Nadeau A, Kinali M, Main M, Jimenez-Mallebrera C, Aloysius A, Clement E, North B, Manzur AY, Robb SA, Mercuri E, Muntoni F. Natural history of Ullrich congenital muscular dystrophy. Neurology 2009; 73:25-31. [PMID: 19564581 DOI: 10.1212/wnl.0b013e3181aae851] [Citation(s) in RCA: 105] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To describe the course, complications, and prognosis of Ullrich congenital muscular dystrophy (UCMD), with special reference to life-changing events, including loss of ambulation, respiratory insufficiency, and death. METHODS Review of the case notes of 13 patients with UCMD, aged 15 years or older at last visit, followed up at a tertiary neuromuscular centre, London, UK, from 1977 to 2007. Data collected were age at onset of symptoms, presenting symptoms, mobility, contractures, scoliosis, skin abnormalities, respiratory function, and feeding difficulties. RESULTS The mean age at onset of symptoms was 12 months (SD 14 months). Eight patients (61.5%) acquired independent ambulation at a mean age of 1.7 years (SD 0.8 years). Nine patients (69.2%) became constant wheelchair users at a mean age of 11.1 years (SD 4.8 years). Three patients continued to ambulate indoors with assistance. Forced vital capacity (FVC) values were abnormal in all patients from age 6 years. The mean FVC (% predicted) declined at a mean rate of 2.6% (SD 4.1%) yearly. Nine patients (69.2%) started noninvasive ventilation at a mean age of 14.3 years (SD 5.0 years). Two patients died of respiratory insufficiency. CONCLUSION In Ullrich congenital muscular dystrophy (UCMD), the decline in motor and respiratory functions is more rapid in the first decade of life. The deterioration is invariable, but not always correlated with age or severity at presentation. This information should be of help to better anticipate the difficulties encountered by patients with UCMD and in planning future therapeutic trials in this condition.
Collapse
Affiliation(s)
- A Nadeau
- Dubowitz Neuromuscular Centre, UCL Institute of Child Health, London, UK
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Nadeau A, Kinali M, Main M, Jimenez-Mallebrera C, North B, Clement E, Manzur A, Robb S, Muntoni F. G.P.1.01 Redefining the clinical spectrum of collagen VI disorders. Neuromuscul Disord 2008. [DOI: 10.1016/j.nmd.2008.06.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
31
|
Hicks D, Lampe A, Laval S, Allamand V, Jimenez-Mallebrera C, Walter M, Muntoni F, Quijano-Roy S, Richard P, Straub V, Lochmuller H, Bushby K. T.O.1 Cyclosporin A as a potential treatment for collagen VI-related muscular dystrophy: A cellular study of mitochondrial dysfunction and its rescue. Neuromuscul Disord 2008. [DOI: 10.1016/j.nmd.2008.06.376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
32
|
Kinali M, Beeson D, Pitt M, Jungbluth H, Simonds A, Aloysius A, Cockerill H, Davis T, Palace J, Manzur A, Jimenez-Mallebrera C, Sewry C, Muntoni F, Robb S. Congenital Myasthenic Syndromes in childhood: Diagnostic and management challenges. J Neuroimmunol 2008; 201-202:6-12. [DOI: 10.1016/j.jneuroim.2008.06.026] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2008] [Revised: 06/07/2008] [Accepted: 06/09/2008] [Indexed: 10/21/2022]
|
33
|
Lampe AK, Zou Y, Sudano D, O'Brien KK, Hicks D, Laval SH, Charlton R, Jimenez-Mallebrera C, Zhang RZ, Finkel RS, Tennekoon G, Schreiber G, van der Knaap MS, Marks H, Straub V, Flanigan KM, Chu ML, Muntoni F, Bushby KMD, Bönnemann CG. Exon skipping mutations in collagen VI are common and are predictive for severity and inheritance. Hum Mutat 2008; 29:809-22. [PMID: 18366090 DOI: 10.1002/humu.20704] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Mutations in the genes encoding collagen VI (COL6A1, COL6A2, and COL6A3) cause Bethlem myopathy (BM) and Ullrich congenital muscular dystrophy (UCMD), two related conditions of differing severity. BM is a relatively mild dominantly inherited disorder characterized by proximal weakness and distal joint contractures. UCMD was originally regarded as an exclusively autosomal recessive condition causing severe muscle weakness with proximal joint contractures and distal hyperlaxity. We and others have subsequently modified this model when we described UCMD patients with heterozygous in-frame deletions acting in a dominant-negative way. Here we report 10 unrelated patients with a UCMD clinical phenotype and de novo dominant negative heterozygous splice mutations in COL6A1, COL6A2, and COL6A3 and contrast our findings with four UCMD patients with recessively acting splice mutations and two BM patients with heterozygous splice mutations. We find that the location of the skipped exon relative to the molecular structure of the collagen chain strongly correlates with the clinical phenotype. Analysis by immunohistochemical staining of muscle biopsies and dermal fibroblast cultures, as well as immunoprecipitation to study protein biosynthesis and assembly, suggests different mechanisms each for exon skipping mutations underlying dominant UCMD, dominant BM, and recessive UCMD. We provide further evidence that de novo dominant mutations in severe UCMD occur relatively frequently in all three collagen VI chains and offer biochemical insight into genotype-phenotype correlations within the collagen VI-related disorders by showing that severity of the phenotype depends on the ability of mutant chains to be incorporated in the multimeric structure of collagen VI.
Collapse
Affiliation(s)
- A K Lampe
- Division of Neurology, The Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Muntoni F, Brockington M, Godfrey C, Ackroyd M, Robb S, Manzur A, Kinali M, Mercuri E, Kaluarachchi M, Feng L, Jimenez-Mallebrera C, Clement E, Torelli S, Sewry CA, Brown SC. Muscular dystrophies due to defective glycosylation of dystroglycan. Acta Myol 2007; 26:129-135. [PMID: 18646561 PMCID: PMC2949305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Muscular dystrophies are a clinically and genetically heterogeneous group of disorders. Until recently most of the proteins associated with muscular dystrophies were believed to be proteins of the sarcolemma associated with reinforcing the plasma membrane or in facilitating its re-sealing following injury. In the last few years a novel and frequent pathogenic mechanism has been identified that involves the abnormal glycosylation of alpha-dystroglycan (ADG). This peripheral membrane protein undergoes complex and crucial glycosylation steps that enable it to interact with LG domain containing extracellular matrix proteins such as laminins, agrin and perlecan. Mutations in six genes (POMT1, POMT2, POMGnT1, fukutin, FKRP and LARGE) have been identified in patients with reduced glycosylation of ADG. While initially a clear correlation between gene defect and phenotype was observed for each of these 6 genes (for example, Walker Warburg syndrome was associated with mutations in POMT1 and POMT2, Fukuyama congenital muscular dystrophy associated with fukutin mutations, and Muscle Eye Brain disease associated with POMGnT1 mutations), we have recently demonstrated that allelic mutations in each of these 6 genes can result in a much wider spectrum of clinical conditions. Thus, the crucial aspect in determining the phenotypic severity is not which gene is primarily mutated, but how severely the mutation affects the glycosylation of ADG. Systematic mutation analysis of these 6 glycosyltransferases in patients with a dystroglycan glycosylation disorder identifies mutations in approximately 65% suggesting that more genes have yet to be identified.
Collapse
Affiliation(s)
- F Muntoni
- Dubowitz Neuromuscular Centre, Department of Paediatrics, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Godfrey C, Clement E, Tan J, Brockington M, Torelli S, Feng L, Brown S, Jimenez-Mallebrera C, Sewry C, Longman C, Mein R, Abbs S, Vajsar J, Schachter H, Muntoni F. C.P.3.04 Mild POMGnT1 mutations underlie a novel limb girdle muscular dystrophy variant. Neuromuscul Disord 2007. [DOI: 10.1016/j.nmd.2007.06.364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
36
|
Feng L, Jimenez-Mallebrera C, Quinlivan R, Muntoni F, Sewry C. G.P.12.12 Non-specific over-expression of utrophin in a variety of neuromuscular disorders including limb girdle muscular dystrophies and congenital myopathies. Neuromuscul Disord 2007. [DOI: 10.1016/j.nmd.2007.06.275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
Hartley L, Kinali M, Knight R, Mercuri E, Hubner C, Bertini E, Manzur AY, Jimenez-Mallebrera C, Sewry CA, Muntoni F. A congenital myopathy with diaphragmatic weakness not linked to the SMARD1 locus. Neuromuscul Disord 2007; 17:174-9. [PMID: 17236770 DOI: 10.1016/j.nmd.2006.11.002] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2006] [Revised: 11/16/2006] [Accepted: 11/21/2006] [Indexed: 11/26/2022]
Abstract
Severe diaphragmatic weakness in infancy is rare. Common causes include structural myopathies, neuromuscular transmission defects, or anterior horn cell dysfunction (spinal muscular atrophy with respiratory distress, SMARD1). We describe a form of infantile diaphragmatic weakness without mutations in the SMARD1 gene, in which pathological and clinical features differ from known conditions, and investigations suggest a myopathy. We identified seven cases in four families. All presented soon after birth with feeding and breathing difficulties, marked head lag, facial weakness, and preserved antigravity movements in the limbs, with arms weaker than legs. All had paradoxical breathing and paralysis of at least one hemi-diaphragm. All required gastrostomy feeding, and all became ventilator-dependent. Investigations included myopathic EMG, muscle biopsy showing myopathic changes, normal electrophysiology and no mutations in SMN1 or IGHMBP2. These seven infants are affected by a myopathic condition clinically resembling SMARD1. However, its pathogenesis appears to be a myopathy affecting predominantly the diaphragm.
Collapse
Affiliation(s)
- L Hartley
- Dubowitz Neuromuscular Centre, Department of Pediatrics, Imperial College, Hammersmith Hospital Campus, Du Cane Road, London W12 ONN, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Jimenez-Mallebrera C, Maioli MA, Kim J, Brown SC, Feng L, Lampe AK, Bushby K, Hicks D, Flanigan KM, Bonnemann C, Sewry CA, Muntoni F. A comparative analysis of collagen VI production in muscle, skin and fibroblasts from 14 Ullrich congenital muscular dystrophy patients with dominant and recessive COL6A mutations. Neuromuscul Disord 2006; 16:571-82. [PMID: 16935502 DOI: 10.1016/j.nmd.2006.07.015] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2006] [Revised: 06/21/2006] [Accepted: 07/03/2006] [Indexed: 11/17/2022]
Abstract
Ullrich congenital muscular dystrophy (UCMD) is caused by recessive and dominant mutations in COL6A genes. We have analysed collagen VI expression in 14 UCMD patients. Sequencing of COL6A genes had identified homozygous and heterozygous mutations in 12 cases. Analysis of collagen VI in fibroblast cultures derived from eight of these patients showed reduced extracellular deposition in all cases and intracellular collagen VI staining in seven cases. This was observed even in cases that showed normal collagen VI labelling in skin biopsies. Collagen VI immunolabelling was reduced in all the available muscle biopsies. When comparisons were possible no correlation was seen between the extent of the reduction in the muscle and fibroblast cultures, the mode of inheritance or the severity of the clinical phenotype. Mutations affecting glycine substitutions in the conserved triple helical domain were common and all resulted in reduced collagen VI. This study expands the spectrum of collagen VI defects and shows that analysis of skin fibroblasts may be a useful technique for the detection of collagen VI abnormalities. In contrast, immunohistochemical analysis of skin biopsies may not always reveal an underlying collagen VI defect.
Collapse
Affiliation(s)
- C Jimenez-Mallebrera
- Dubowitz Neuromuscular Centre, Imperial College, Hammersmith Hospital, London, UK.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Abstract
The congenital muscular dystrophies are a clinically and genetically heterogeneous group of neuromuscular disorders. Each form has a characteristic phenotype, but there is overlap between some entities and their classification is based on a combination of clinical features and the primary or secondary protein defect. Recent studies have identified the genetic basis of a number of congenital muscular dystrophies (11 genes in total) and have recognised a novel pathological mechanism that highlights the importance of the correct posttranslational processing of proteins, in particular alpha-dystroglycan. Diagnosis of these conditions has been aided by the availability of specific antibodies for each protein and a better understanding of the protein changes that accompany each condition. In this review we present the major molecular, clinical and diagnostic aspects of each group of congenital muscular dystrophy with an emphasis in the more recent developments.
Collapse
Affiliation(s)
- C Jimenez-Mallebrera
- Dubowitz Neuromuscular Centre, Imperial College, Hammersmith Hospital Campus, Du Cane Road, London W12 ONN, United Kingdom.
| | | | | | | |
Collapse
|
40
|
Torelli S, Brown SC, Jimenez-Mallebrera C, Feng L, Muntoni F, Sewry CA. Absence of neuronal nitric oxide synthase (nNOS) as a pathological marker for the diagnosis of Becker muscular dystrophy with rod domain deletions. Neuropathol Appl Neurobiol 2004; 30:540-5. [PMID: 15488030 DOI: 10.1111/j.1365-2990.2004.00561.x] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Immunohistochemistry using antibodies to dystrophin is the pathological basis for the diagnosis of Duchenne and Becker muscular dystrophy (DMD and BMD). While the sarcolemma of DMD muscle is negative, BMD muscle generally shows variable labelling because of the translation of a partially functional dystrophin that is localized to the sarcolemma. In rare cases, however, this labelling is equivocal and similar to that observed in controls making diagnosis difficult. We report here that in such instances immunolabelling with antibodies to the neuronal form of nitric oxide synthase (nNOS) can be useful in suspecting a dystrophinopathy with a mutation in the 'hot-spot' rod domain and help to direct molecular analysis. nNOS localizes to the sarcolemma of mature muscle fibres via several components of the dystrophin-associated protein complex (DAPC) including dystrophin but sarcolemmal nNOS is lost when dystrophin levels are very low or absent because of deletions in critical regions of the rod domain. We report three cases who presented with only mild or no muscle weakness but had elevated serum creatine kinase activity and dystrophin immunolabelling indistinguishable from normal, making a pathological diagnosis difficult. All three cases had a complete absence of sarcolemmal nNOS and were subsequently found to have an in-frame deletion in the common rod domain exons (in these cases 48, 45-51, 47-53) compatible with a BMD. In addition, we observed that nNOS appears to be developmentally regulated with the antibody used and was often absent from the sarcolemma of immature fibres. These findings demonstrate the value of including antibodies to nNOS in routine immunohistochemical studies and that absence of nNOS can be a more sensitive marker than up-regulation of utrophin for diagnosis of BMD. Immaturity of fibres, however, needs to be taken into account, especially in neonates.
Collapse
Affiliation(s)
- S Torelli
- The Dubowitz Neuromuscular Centre, Department of Paediatrics & Neonatal Medicine, Imperial College London, London, UK.
| | | | | | | | | | | |
Collapse
|